Following the recent Supreme Court of Canada decision in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, this webinar will provide insight on patentable subject matter in Canada and, in particular, whether dosing regimens constitute unpatentable methods of medical treatment under the Patent Act. This appeal marked the first time in over 50 years that the Supreme Court has directly confronted the patentability of methods of medical treatment.
The Court's ruling reaffirms the long-standing prohibition and substantially adopts the approach of the Federal Court of Appeal. The webinar will examine the Court's guidance for distinguishing patentable subject matter from professional skill and judgment, the concurring reasons that would have removed the prohibition entirely, and the decision's practical implications for patent drafting and prosecution.
